SCHEMBL735334

SCHEMBL735334

CC(C)(C)OC(=O)CCN(CC=O)c1cccc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
BCL2A1 Q16548 1/20 0.35
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
XPO1 O14980 1/20 0.34
KDM4E B2RXH2 2/20 0.33
TACR1 P25103 1/20 0.33
RABGGTB P53611 1/20 0.33
RABGGTA Q92696 1/20 0.33
CRHR1 P34998 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735619 0.85 ALOX15 (0.37) MAPTALDH1A1HTTSMN1; SMN2RXRA
SCHEMBL734806 0.84 CETP (0.37) MAPTNPC1RAB9ARXRARXRB
SCHEMBL735628 0.83 CETP (0.40)
SCHEMBL1555959 0.81 KCNH2 (0.34) RXRA
SCHEMBL1555167 0.79 APP (0.40)
SCHEMBL736294 0.78 MAPT (0.37) MAPTALDH1A1NPC1HTTRAB9A
SCHEMBL30358877 0.78 BCL2A1 (0.43) MAPTKMT2AALDH1A1NPC1GAA
SCHEMBL31464829 0.78 BCL2A1 (0.43) MAPTKMT2AALDH1A1NPC1GAA
SCHEMBL736799 0.76 EPHX2 (0.37) MEN1KMT2AGAAHTTKDM4E
SCHEMBL11714694 0.71 SMN1; SMN2 (0.48) MAPTMEN1KMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 MAPT 4751/4885MEN1 4064/4885KMT2A 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.